Background {#Sec1}
==========

HZ or shingles is caused by the reactivation of the varicella zoster virus (VZV), for which primary infection manifests as chickenpox, or varicella. The estimated lifetime risk for the development of HZ is approximately 30% \[[@CR1]--[@CR3]\]. Rash onset, the typical clinical feature of HZ, is characterized by a unilateral, dermatomal rash with vesicular lesions that usually heal within 2--4 weeks \[[@CR4]\]. Pain during this phase, which ranges from moderate-to-severe in the majority of patients \[[@CR5]\], negatively impacts functional status and QoL with greater acute pain burden significantly associated with poorer physical role, social functioning, and greater emotional distress \[[@CR5]--[@CR8]\]. HZ has also been shown to be responsible for cases of absenteeism, presenteeism (defined as attending work while sick) and decreased work effectiveness \[[@CR9]--[@CR11]\], with combined work loss varying significantly by disease severity \[[@CR10]\]. Consequently, HZ has a significant negative effect on the productive work life of individuals; consideration of this effect on work and productivity therefore contributes to the cost-effectiveness of HZ therapeutic interventions, specifically those aiming at preventing VZV reactivation.

However, the true cost-effectiveness of therapeutic interventions for HZ may be underestimated. This is emphasized by discrepancies in guidelines for cost-effectiveness analysis, which differ as to whether work time loss should be included in the numerator of the incremental cost-effectiveness ratio (ICER), or as an implicit consideration of health state valuations, which are contained in the denominator of the ICER. This is due to the fact that it is unclear whether or not people actually take into account the effect of disease on their ability to work, and the resulting lost wages, when evaluating health states \[[@CR12]--[@CR14]\]. The Panel on Cost-Effectiveness in Health and Medicine have nevertheless recently put forth revised recommendations advocating for the inclusion of these effects in the numerator in the ICER \[[@CR15]\].

The MASTER (Monitoring and Assessing Shingles Through Education and Research) studies, were prospective cohort studies conducted in 8 countries \[[@CR16]--[@CR19]\], which assessed Herpes Zoster (HZ)-related burden of illness, including pain, health related quality of life (HRQoL), health care resource utilisation (HCRU), and associated cost. Using data from these studies, the aim of this pooled analysis was to examine the association of HZ-related work time loss, or HZ-related work productivity loss, with HRQoL, to evaluate whether or not patients with work time loss have lower health utility scores than those without, and to identify predictors of HRQoL in an active population of HZ patients.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a pooled analysis of the MASTER studies conducted in 8 countries, which shared the same design and were conducted using similar methodology \[[@CR16]--[@CR19]\]. The objectives of the MASTER study were to measure HZ-related burden of illness, HRQoL, health care resource utilisation (HCRU), and out of pocket costs. Among the 1477 patients enrolled overall, 428 were engaged in full or part time work (active population) and were, thus, included in the current analysis, with the following geographic distribution: Latin America (*n* = 128), consisting of Argentina (*n* = 37), Brazil (*n* = 36), Costa Rica (*n* = 6), and Mexico (*n* = 49); North America, consisting of Canada (*n* = 160); and Asia (*n* = 140), consisting of Korea (*n* = 45), Taiwan (*n* = 49), and Thailand (*n* = 46).

Patient population {#Sec4}
------------------

Patients eligible for cohort inclusion were either male or female patients ≥ 50 years of age with HZ rash or residual HZ-associated pain, defined as pain persisting subsequent to rash healing. In addition, in order to be included in this analysis, patients had to belong to the active population (actively employed in full or part time work). Incident cases were defined as patients recruited from the offices of general practitioners or specialists for a current HZ episode (rash onset or start of pain) with a duration of ≤ 7 days; prevalent cases were defined as patients enrolled experiencing a HZ episode which had lasted longer than 7 days, with the onset of rash recorded in medical records. Key exclusion criteria were the presence of any medical condition that, in the opinion of the treating physician, could interfere with the evaluations required by the study, and patient and/or family member or primary caregiver refusal to sign informed consent.

Treatment and follow-up {#Sec5}
-----------------------

In accordance with the observational nature of the studies, any treatment of the HZ-episode was based on the judgement of the treating physician. After the baseline assessment at Day 0, patients were followed for a maximum of 6 months. Regardless of the phase of disease at the time of enrolment, 9 follow-up assessments were recommended at Days 7, 14, 21, 30, 60, 90, 120, 150 and 180, to a total of 10 visits, with the exception of Korea and Taiwan, in which prevalent cases were assessed at every month after the baseline visit, for a total of 7 visits overall. The baseline (Day 0) assessment was conducted at the physician's office, and follow-up assessments were conducted though self-administered questionnaires. At baseline, information regarding the patient's immune status, pain-related medical history, demographics, current medications, and characteristics of the current HZ-episode, was collected. The outcome measures described in the following section were evaluated at each patient assessment.

Pooled analysis outcome measures {#Sec6}
--------------------------------

### Work productivity and work time loss {#Sec7}

Work productivity of patients and/or caregivers was measured at every patient assessment irrespective of the presence of HZ rash and/or pain using a simple descriptive, self-administered, standardized questionnaire, the Work and Productivity Questionnaire (WPQ) (Additional file [1](#MOESM1){ref-type="media"}). The WPQ evaluated the number of times work was missed (full and half days), with Work Time Loss defined as missing ≥ 1 partial or full work day. The principal causes of absences (health care visits, pain, discomfort, lack of concentration, visible rash, or medication side effects), and whether or not extended sick leave, disability, or use of vacation time was required, was also assessed. In addition, patients were asked to rate their productivity (effectiveness) at work during their shingles episode on a scale of 0--100%.

### Health related quality of life {#Sec8}

HRQoL was captured using the Euro-QoL (EQ-5D) questionnaire \[[@CR20]\], a generic health status instrument which evaluates quality of life based on the measurement of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A preference based scale, the EQ-5D assesses each dimension with three levels of severity; 1 (no problems), 2 (some problems), and 3 (maximum problems). Each score can then be weighted to adjust for population-specific preferences in health-care states. For the purposes of this analysis, UK weights, the most validated weights, were used to convert individual health dimensions scores to a single EQ-5D summary score, with EQ-5D summary scores closest to 1 indicative of a better quality of life. The VAS component of the EQ-5D questionnaire (EQ-5D VAS) also records the patient's self-rated health on a horizontal scale, ranging from "worst imaginable health state" to "best imaginable health state". At the baseline visit (Day 0), each patient was required to complete two EQ-5D questionnaires, one to assess their usual quality of life prior to HZ onset, and another to assess their current state of health during the current HZ episode.

### HZ-associated pain {#Sec9}

HZ-associated pain was evaluated with the Zoster Brief Pain Inventory (ZBPI) questionnaire \[[@CR21]\] and the Initial Zoster Impact Questionnaire (IZIQ). The ZBPI is a 9 question HZ-specific questionnaire which evaluates two components of pain, intensity and interference, on an 11 point Likert scale. More specifically, the ZBPI measures the presence and location of pain, the severity of the worst, least, and average pain in the last 24 h, current pain intensity, use of medications, use of relief medications, and the interference of pain on general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. The IZIQ, completed only at baseline, was used to complement the ZBPI, which was completed at all Study Visits, by assessing pain prior to study enrolment \[[@CR16]--[@CR19]\].

Statistical analysis {#Sec10}
--------------------

Descriptive statistics were produced for all relevant variables, including the mean and standard deviation for continuous scale variables, and frequency distributions for categorical variables. In addition to the total active population, all analyses were stratified by Work Time Loss Category (Work Time Loss (WTL) versus No Work Time Loss (NWTL)). Significance was determined *a priori* at *p* \< 0.05, and a statistical trend was defined at *p* \< 0.150.

For assessment of the correlation between HRQoL (EQ-5D item scores: domain scores, overall summary score and VAS) and percentage of work effectiveness, the Pearson product--moment correlation was used. To identify predictors of HRQoL, mixed models with repeated measures were used, where individual EQ-5D scores throughout the follow-up period were the dependent variable, and the following covariates were considered: Work Time Loss Category (WTL versus NWTL), age at rash onset, gender, impaired immune status, presence of HZ complications, severity of rash at baseline (number of HZ lesions), worst pain score at baseline (based on the ZBPI "worst pain in the last 24 h" score), employment status (full-time versus part time), geographic region, and country income. Impaired immune status was defined as the use of high dose oral corticosteroids, invasive cancers (with the exception of CIS and non-melanoma skin cancer), HIV infection/ AIDS, immune deficiency, receipt of chemotherapy for cancer, prior or concurrent immunosuppressive therapy, or receipt of immunosuppressive therapy for organ transplant. Country income categories were determined according to the 2016 World Bank Income categories: upper-middle-income economies were defined as those with a gross national income (GNI) per capita of more than \$4126 but less than \$12,735; high-income economies were defined as those with a GNI per capita of \$12,735 or more \[[@CR22]\].

Results {#Sec11}
=======

Baseline socio-demographic and disease characteristics {#Sec12}
------------------------------------------------------

Baseline socio-demographic and disease characteristics are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively, and are presented overall, as well as stratified by whether or not the patient experienced work time loss (WTL group vs. NWTL group). Of the 428 patients included in the analysis, 247 (57.7%) reported losing work time due to their current HZ episode, with 147 patients (34.3%), reporting no work time loss. Information on work time loss was not available for 34 patients (7.9%) (Table [1](#Tab1){ref-type="table"}). Overall, the mean (SD) age of rash onset was 58.9 (7.2) years, with over 60% of patients between the ages of 50--59. No significant differences were reported in baseline socio-demographic characteristics, with the exception of geographic region, where the proportion of patients from Asian, Latin and North American countries differed across both the WTL and NWTL groups (*p =* 0.010) (Table [1](#Tab1){ref-type="table"}). The majority of patients (*n* = 336; 78.5%) were employed full time, and 92 (21.5%) were part-time workers. Regarding work effectiveness, mean (SD) percent work effectiveness of patients in the WTL group was significantly lower compared to the NWTL group at baseline \[50.3 (31.6) vs. 71.4 (27.8); *p* \< 0.001\], with a significantly greater proportion of patients in the WTL group reporting a decrease in work effectiveness (89.1% in the WTL group versus, 66.0% in the NWTL group; *p \<* 0.001) (Table [1](#Tab1){ref-type="table"}). Overall, mean (SD) work time loss reported was 9.1 (15.6) days.Table 1Baseline socio-demographic characteristics overall and by Work Time Loss CategoryVariableWork time loss categoryOverall^b^*p*-valueWork time loss^a^No work time lossTotal n, %247 (57.7)147 (34.3)428-Age at rash onset, years, mean (SD)59.0 (7.4)58.6 (7.1)58.9 (7. 2)0.674Gender, female, n (%)126 (51.0)71 (48.3)217 (50.7)0.602Age category at rash onset, years, n (%) 50--59148 (59.9)95 (64.6)263 (61.4) 60--6979 (32.0)39 (26.5)129 (30.1)0.520  ≥ 7020 (8.1)13 (8.8)35 (8.2) Not Available0 (0.0)0 (0.0)1 (0.2)Education, n (%) Primary school or less54 (21.9)25 (17.0)86 (20.1) High school77 (31.2)51 (34.7)139 (32.5)0.485 College/University114 (46.2)69 (46.9)199 (46.5) Not Available2 (0.8)2 (1.4)4 (0.9)Geographic region, n (%)^c^ Asia77 (31.2)52 (35.4)140 (32.7) Latin America91 (36.8)33 (22.4)128 (29.9)0.010 North America79 (32.0)62 (42.2)160 (37.4)Country category (income)^d^ Upper-Middle94 (38.1)42 (28.6)146 (34.1) High93 (37.7)64 (43.5)171 (40.0)0.079 Not Available60 (24.3)41 (27.9)111 (25.9)Employment status, n (%) Full time200 (81.0)112 (76.2)336 (78.5) Part time47 (19.0)35 (23.8)92 (21.5)0.258Number of hours work overall/week  *n*246146411 Mean (SD)39.3 (16.0)38.3 (17.6)38.8 (16.5)0.395Number of hours part time work/week  *n*473489 Mean (SD)23.3 (11.5)22.9 (11.7)23.6 (12.2)0.939Number of hours full time work /week  *n*199112322 Mean (SD)43.1 (14.4)43.0 (16.4)43.0 (15.0)0.703Total number persons/household  *n*243145421 Mean (SD)2.8 (1.6)3.0 (1.9)2.8 (1.7)0.420Type of household, n (%) Apartment76 (30.8)48 (32.7)134 (31.3) House170 (68.8)97 (66.0)291 (68.0)0.838 Other1 (0.4)1 (0.7)2 (0.5) Not Available0 (0.0)1 (0.7)1 (0.2)Work effectiveness, mean percent, (SD)50.3 (31.6)71.4 (27.8)56.0 (32.0)\<0.001Work effectiveness category, n (%) 100%20 (8.1)41 (27.9)67 (15.7) 50--90%122 (49.4)71 (48.3)206 (48.1)\<0.001 10--40%61 (24.7)19 (13.0)87 (20.3) 0%37 (15.0)7 (4.8)10 (2.3) Not Available7 (2.8)9 (6.1)18 (4.2)^a^Patients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, as assessed by the WPQ^b^34 patients did not have information on Work Time Loss Category^c^Asia = Korea, Taiwan, Thailand; Latin America = Argentina, Brazil, Costa Rica, Mexico; North America = Canada^d^Country income classifications are based on the 2016 World Bank economic definitions \[[@CR22]\]. High Income= Canada, South Korea, Taiwan, Argentina; Upper Middle Income= Brazil, Costa Rica, Mexico, Thailand Table 2Baseline disease parameters overall and by Work Time Loss CategoryVariableWork Time Loss CategoryOverall^b^*p*-valueWork Time Loss^a^No Work Time LossTotal n, %247 (57.7)147 (34.3)428-Time from HZ onset, days  *n*247147427 Mean (SD)124.2 (458.3)79.6 (284.2)128.6 (476.6)\<0.001Time from HZ onset - categorical, n (%) Incident74 (30.0)65 (44.2)154 (36.0) Prevalent173 (70.0)82 (55.8)273 (63.8)0.004 Not available0 (0.0)0 (0.0)1 (0.2)Pain before rash appearance, n (%) Yes156 (63.2)89 (60.5)260 (60.7) No79 (32.0)52 (35.4)146 (34.1)0.520 Not available12 (4.9)6 (4.1)22 (5.1)Average pain score before rash appearance^c^  *n*15588258 Mean (SD)4.9 (2.6)4.4 (2.5)4.7 (2.6)0.148Worst pain before rash appearance^c^  *n*15486255 Mean (SD)6.4 (2.6)5.8 (2.5)6.2 (2.6)0.057Pain since rash appearance, n (%) Yes222 (89.9)130 (88.4)376 (87.9) No14 (5.7)12 (8.2)33 (7.7)0.349 Not available11 (4.5)5 (3.4)19 (4.4)Average pain since rash appearance^c^  *n*222129375 Mean (SD)5.6 (2.3)4.7 (2.2)5.3 (2.3)0.002Worst pain since rash appearance^c^  *n*221128373 Mean (SD)7.6 (2.3)6.5 (2.5)7.2 (2.5)\<0.001Pain in the last 24 hs Yes224 (90.7)126 (85.7)380 (88.8) No23 (9.3)20 (13.6)47 (11.0)0.178 Not available0 (0.0)1 (0.7)1 (0.2)Average pain in last 24 h^c^  *n*224126380 Mean (SD)4.5 (2.5)4.0 (2.3)4.3 (2.4)0.062Worst pain in last 24 h^c^  *n*220124372 Mean (SD)6.2 (2.6)5.4 (2.6)5.9 (2.6)0.004Worst pain score category, n (%)^d^ Mild43 (17.4)35 (23.8)83 (19.4) Moderate91 (36.8)55 (37.4)161 (37.6)0.041 Severe86 (34.8)33 (22.4)127 (29.7) Not available27 (10.9)24 (16.3)57 (13.3)Severity of rash (number of lesions), n (%) No rash56 (22.7)18 (12.2)84 (19.6) Mild (1--20)107 (43.3)86 (58.5)207 (48.4) Moderate (21--50)49 (19.8)24 (16.3)77 (18.0)0.014 Severe (\>50)35 (14.2)18 (12.2)59 (13.8) Not available0 (0.0)1 (0.7)1 (0.2)Impaired immune status^e^ Yes18 (7.3)9 (6.1)29 (6.8) No229 (92.7)138 (93.9)399 (93.2)0.658Presence of HZ complication Yes80 (32.4)40 (27.2)136 (31.8) No166 (67.2)107 (72.8)291 (68.0)0.269 Not available1 (0.4)0 (0.0)1 (0.2)Medication for HZ Yes23 (9.3)24 (16.3)51 (11.9) No224 (90.7)123 (83.7)377 (88.1)0.038*SD* standard deviation, *HZ* Herpes Zoster, *CIS* carcinoma in situ, *HIV* human immunodeficiency virus, *AIDS* acquired immune deficiency syndrome^a^Patients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, as assessed by the WPQ^b^34 patients did not have information on Work Time Loss Category^c^Measured on an 11 point Likert scale which ranges from "no pain" (0) to "pain as bad as you can imagine" (11)^d^Worst pain score categories are based on the ZPBI "worst pain in the last 24 h" scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores 4- ≤ 7; severe worst pain = ZBPI score ≥8^e^Defined as: use of high dose oral corticosteroids, invasive cancers (with the exception of CIS and non-melanoma skin cancer), HIV infection/ AIDS, immune deficiency, chemotherapy for cancer, prior or concurrent immunosuppressive therapy, and therapy for organ transplant

At baseline, rash was predominately absent or mild in severity (68.0%, *n* = 291), with significant differences observed between the WTL and NWTL groups (*p* = 0.014) in terms of the proportion of patients reporting no rash (22.7% WTL vs. 12.2% NWTL), mild rash (43.3% WTL vs. 58.5% NWTL), moderate rash (19.8% WTL vs. 16.3% NWTL), and severe rash (14.2% WTL vs. 12.2% NWTL), and more patients in the NWTL group administered medication for their HZ episode (9.3% WTL vs. 16.3% NWTL; *p* = 0.038) (Table [2](#Tab2){ref-type="table"}). Time from HZ onset was also significantly longer in the WTL group compared to the NWTL group \[124.2 (458.3) vs. 79.6 (284.2) days; *p* \< 0.001\].

Generally, at baseline, patients in the WTL group reported more severe disease parameters, with significant differences found for worst pain in the last 24 h \[6.2 (2.6) WTL vs. 5.4 (2.6) NWTL; *p* = 0.004\] and average and worst pain since rash experience \[5.6 (2.3) WTL vs. 4.7 (2.2) NWTL, *p =*0.002; 7.6 (2.3) WTL vs. 6.5 (2.5) NWTL; *p* \< 0.001, respectively\]; although differences in the proportion of patients experiencing post-rash pain were not significant (*p* = 0.349) (Table [2](#Tab2){ref-type="table"}). In addition, a significant difference in worst pain (based on the ZBPI "worst pain in the last 24 h" score) was found between Work Time Loss Categories, with an overall greater proportion of patients in the WTL group reporting severe worst pain compared to the NWTL group (34.8% vs. 22.4%; *p* = 0.041) (Table [2](#Tab2){ref-type="table"}). Duration of pain, i.e. from baseline to resolution, was also significantly higher in the WTL group compared to the NWTL group \[89.9 (193.7) vs. 53.4 (51.4) days; *p* \< 0.001\]. No significant differences were found between groups with regards to prodromal pain. Moreover, at baseline, patients in the WTL group had significantly lower (*p* \< 0.001) overall HRQoL (EQ-5D summary score), greater problems with self-care and usual activities, and experienced higher pain/discomfort, when compared to patients in the NWTL group (Table [3](#Tab3){ref-type="table"}). Pooled across all visits, significantly lower (*p* \< 0.001) scores were seen in the WTL group for both overall HRQoL (EQ-5D summary score and VAS) and individual EQ-5D dimensions (Table [3](#Tab3){ref-type="table"}).Table 3EQ-5D items and scores at baseline and pooled over timeVariableBaselinePooled visits^c^Work time loss^a^No work time lossOverall^b^*p*-valueWork time loss^a^No work time lossOverall^b^*p*-valueTotal n^d^247147428-78621483738Mobility, n (%) I have no problems in walking174 (70.4)117 (79.6)318 (74.3)554 (71.9)1876 (89.7)3019 (80.9) I have some problems in walking65 (26.3)29 (19.7)99 (23.1)202 (26.2)184 (8.8)553 (14.8) I am confined to a bed5 (2.0)0 (0.0)5 (1.2)0.0518 (1.0)4 (0.2)13 (0.3)\<0.001 Not available3 (1.2)1 (0.7)6 (1.4)7 (0.9)27 (1.3)147 (3.9)Self-care, n (%) I have no problems in self-care191 (77.3)132 (89.8)351 (82.0)631 (81.8)1988 (95.1)3260 (87.4) I have some problems washing and dressing49 (19.8)13 (8.8)66 (15.4)125 (16.2)71 (3.4)310 (8.3) I am unable to wash and dress myself4 (1.6)1 (0.7)5 (1.2)0.0058 (1.0)5 (0.2)15 (0.4)\<0.001 Not available3 (1.2)1 (0.7)6 (1.4)7 (0.9)27 (1.3)147 (3.9)Usual activities, n (%) I have no problems with performing usual activities124 (50.2)102 (69.4)249 (58.2)375 (48.6)1773 (84.8)2695 (72.2) I have some problems performing usual activities103 (41.7)41 (27.9)153 (35.7)357 (46.3)283 (13.5)821 (22.0) I am unable to perform usual activities17 (6.9)3 (2.0)20 (4.7)0.00132 (4.2)8 (0.4)69 (1.8)\<0.001 Not available3 (1.2)1 (0.7)6 (1.4)7 (0.9)27 (1.3)147 (3.9)Pain/Discomfort, n (%) I have no pain or discomfort54 (21.9)45 (30.6)110 (25.7)197 (25.6)1379 (65.9)1955 (52.4) I have moderate pain or discomfort142 (57.5)84 (57.1)245 (57.2)459 (59.5)655 (31.3)1428 (38.3) I am extreme pain or discomfort48 (19.4)17 (11.6)67 (15.7)0.044108 (14.0)30 (1.4)202 (5.4)\<0.001 Not available3 (1.2)1 (0.7)6 (1.4)7 (0.9)27 (1.3)147 (3.9)Anxiety/Depression, n (%) I am not anxious or depressed122 (49.4)88 (59.9)230 (53.7)381 (49.4)1672 (80.0)512 (58.9) I am moderately anxious or depressed96 (38.9)49 (33.3)156 (36.4)325 (42.2)367 (17.6)910 (24.4) I am extremely anxious or depressed26 (10.5)9 (6.1)36 (8.4)0.09758 (7.5)25 (1.2)110 (2.9)\<0.001 Not available3 (1.2)1 (0.7)27 (3.1)7 (0.9)27 (1.3)147 (3.9)EQ-5D summary scores based on UK weight  *n*24414642276420643585 Mean (SD)0.6 (0.4)0.7 (0.3)0.6 (0.3)0.0010.6 (0.3)0.9 (0.2)0.8 (0.3)\<0.001VAS, mm  *n*24414542176320593572 Mean (SD)66.7 (23.7)71.1 (20.5)68.5 (22.4)0.10668.1 (22.6)86.5 (16.6)80.3 (21.0)\<0.001*SD* standard deviation, *VAS* visual analogue scale, *WPQ* Work and Productivity Questionnaire^a^Patients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any of the follow-up visits (Visits 2--10) as assessed by the WPQ^b^34 patients did not have information on Work Time Loss Category^c^Visits 1--10^d^Total n's are based on cumulative visits

Correlation analyses {#Sec13}
--------------------

Table [4](#Tab4){ref-type="table"} presents the correlation between percentage of work effectiveness and all EQ-5D items (dimension scores, summary score, and the VAS), overall, and by Work Time Loss Category. All correlation coefficients (*r)* reported were found to be statistically significant (*p \<* 0.001). Overall, percent work effectiveness was negatively correlated with all 5 dimension scores, whereas the EQ-5D summary score and VAS were positively correlated with percentage of work effectiveness (*r* = 0.427 and 0.490, respectively) suggesting that higher work productivity is associated with improved HRQoL. Similar results were observed for the WTL group, although a stronger correlation was observed for percent work effectiveness per the NWTL group versus the WTL group. This was evident in particular with regards to the EQ-5D overall summary score (NWTL: *r =* 0.402 vs. WTL *r =* 0.209) and the VAS (NWTL: *r =* 0.511 vs. WTL: *r* = 0.260).Table 4Correlation between EQ-5D item scores and percentage of work effectiveness overall and by Work Time Loss CategoryVariableWork Time Loss CategoryEQ-5D item scoresCorrelation coefficient ^b^*P*-valuePercent work effectiveness^c^OverallMobility−0.265\<0.001Self-Care−0.243\<0.001Usual activities−0.401\<0.001Pain/Discomfort−0.396\<0.001Anxiety/Depression−0.331\<0.001EQ-5D summary scores based on UK weight0.427\<0.001EQ-5D VAS0.490\<0.001Mobility−0.238\<0.001Self-Care−0.158\<0.001Usual activities−0.323\<0.001No Work Time LossPain/Discomfort−0.356\<0.001Anxiety/Depression−0.329\<0.001EQ-5D summary scores based on UK weight0.402\<0.001EQ-5D VAS0.511\<0.001Mobility−0.148\<0.001Self-Care−0.162\<0.001Usual activities−0.245\<0.001Work Time Loss^a^Pain/Discomfort−0.161\<0.001Anxiety/Depression−0.140\<0.001EQ-5D summary scores based on UK weight0.209\<0.001EQ-5D VAS0.260\<0.001*WPQ* Work and Productivity Questionnaire, *VAS* visual analogue scale^a^Patients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any of the follow-up visits (Visits 2--10) as assessed by the WPQ^b^Correlation coefficient was calculated based on Pearson's correlation measure^c^Pooled over time (Visits 1--10)

Multivariate analyses {#Sec14}
---------------------

Upon adjusting for Work Time Loss Category, individual predictors of quality of life (both the EQ-5D summary score and the VAS) were time since HZ onset, worst pain score, severity of rash at baseline, geographic region, and country income (Table [5](#Tab5){ref-type="table"}). Presence of HZ complications was also identified as a potential predictor of the VAS. Significant independent predictors of EQ-5D overall summary score identified in the saturated multivariate model are presented in Table [6](#Tab6){ref-type="table"}. Work time loss was identified as a significant negative predictor of HRQoL with regards to both the EQ-5D overall summary score and the VAS (*p* \< 0.001), as was moderate/severe worst pain score compare to mild pain (*p* \< 0.001). Increased severity of rash was associated with significantly higher EQ-5D summary score, (*p* = 0.042 for mild vs. no rash; *p* = 0.206 for moderate vs. no rash; *p* = 0.017 for severe vs. no rash), whereas country income (high vs. upper middle income levels) and presence of HZ complications, were both significant negative predictors (*p* = 0.003, and *p* = 0.007) of the VAS.Table 5Repeated measures mixed model analysis assessing individual predictors of the EQ-5D summary score and EQ-5D VASEQ-5D ItemEQ-5D overall summary scoreEQ-5D VASPredictorEstimate^a^SD95% CI for estimate*p*-valueEstimate^a^SD95% CI for estimate*p*-valueWork Time Loss Category Work Time Loss^b^ vs. No Work Time Loss−0.2340.010−0.254, −0.215\<0.001−16.920.755−18.40, −15.44\<0.001Time from HZ onset - categorical Prevalent vs. incident−0.0490.014−0.076, −0.022\<0.001−3.8111.339−6.442, −1.1810.005Age category at rash onset, years^c^ 60--69 vs. 50--59−0.0020.015−0.032, 0.0280.898−1.5621.465−4.441, 1.3180.287  ≥ 70 vs. 50--59−0.0420.026−0.092, 0.0080.100−2.7852.472−7.643, 2.0730.260Worst Pain Category^c,d^ Moderate vs. mild−0.0840.013−0.111, −0.058\<0.001−8.8421.075−10.95, −6.732\<0.001 Severe vs. mild−0.2870.018−0.323, −0.251\<0.001−14.081.447−16.92, −11.24\<0.001Severity of rash (number of lesions)^c^ Mild (1--20) vs.no rash0.1090.0170.074, 0.143\<0.00110.6461.7077.292, 14.000\<0.001 Moderate (21--50) vs. no rash0.1000.0210.058, 0.141\<0.0018.8922.0644.837, 12.947\<0.001 Severe (\>50) vs. no rash0.0950.0240.049, 0.142\<0.0019.6842.2785.207, 14.160\<0.001Gender^c^ Male vs. female−0.0050.013−0.032, 0.0210.6910.8331.295−1.711, 3.3770.520Impaired immune status^c,\ e^ Yes vs. no−0.0340.025−0.084, 0.0160.181−1.8762.472−6.734, 2.9830.448Presence of complications from HZ^c^ Yes vs. no−0.0120.014−0.040, 0.0160.400−5.0161.370−7.707, −2.324\<0.001Employment status^c^ Full time vs. part time0.0080.016−0.024, 0.0400.612−1.9191.574−5.011, 1.1730.223Geographic region^c,f^ Latin America vs. Asia0.0300.017−0.004, 0.0640.1913.2451.6280.047, 6.4430.098 North America vs. Asia−0.0430.017−0.076, −0.0100.011−5.1461.583−8.257, −2.0350.001Country category (income)^c,\ g^ High vs. Upper Middle−0.0520.014−0.079, −0.026\<0.001−6.6161.290−9.151, −4.081\<0.001*SD* standard deviation, *CI* confidence interval, *HZ* Herpes Zoster, *WPQ* Work and Productivity Questionnaire, *ZBPI* Zoster Brief Pain Inventory, *VAS* visual analogue scale, *CIS* carcinoma in situ, *HIV* human immunodeficiency virus, *AIDS* acquired immune deficiency syndrome^a^The estimate is the relative effect of the predictor on EQ-5D scores compared to the reference group^b^Patients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any of the follow-up visits (Visits 2--10) as assessed by the WPQ^c^Predictors were adjusted by Work Time Loss Category^d^Worst pain score categories are based on the ZBPI "worst pain in the last 24 h" scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores 4- ≤ 7; severe worst pain = ZBPI score ≥8^e^ Defined as: use of high dose oral corticosteroids, invasive cancers (with the exception of CIS and non-melanoma skin cancer), HIV infection/ AIDS, immune deficiency, chemotherapy for cancer, prior or concurrent immunosuppressive therapy, and therapy for organ transplant^f^Asia = Taiwan, Thailand, South Korea; Latin America = Argentina, Brazil, Costa Rica; Mexico; North America = Canada^g^Country income classifications are based on the 2016 World Bank economic definitions \[[@CR22]\]. High Income= Canada, South Korea, Taiwan, Argentina; Upper Middle Income= Brazil, Costa Rica, Mexico, Thailand Table 6Saturated multivariate repeated measures mixed model assessing independent predictors of the EQ-5D summary score and EQ-5D VASEQ-5D ItemEQ-5D overall summary scoresEQ-5D VASPredictorEstimate^a^SD95% CI for estimate*p*-valueEstimate^a^SD95% CI for estimate*p*-valueWork Time Loss Category Work Time Loss^b^ vs. No Work Time Loss−0.1020.014−0.129, −0.074\<0.001−6.5111.109−8.687, −4.336\<0.001Time from HZ onset - categorical Prevalent vs. incident−0.0160.019−0.052, 0.0200.387−0.8711.754−4.320, 2.5780.620Worst Pain Category^c^ Moderate vs. mild−0.0830.014−0.109, −0.056\<0.001−8.7611.079−10.88, −6.643\<0.001 Severe vs. mild−0.2900.018−0.326, −0.254\<0.001−14.401.445−17.23, −11.56\<0.001Severity of rash (number of lesions) Mild (1--20) vs. no rash0.0440.0210.002, 0.0860.0424.1502.1280.035, 8.3340.052 Moderate (21--50) vs. no rash0.0350.028−0.019, 0.0900.2063.7552.667−1.489, 8.9990.160 Severe (\>50) vs. no rash0.0700.0290.012, 0.1280.0174.6212.865−1.014, 10.2550.108Country category (income)^d^ High vs. Upper Middle−0.0270.033−0.091, 0.0380.413−8.5322.902−14.24, −2.8280.003Geographic region^e^ Latin America vs. Asia0.0210.032−0.042, 0.0830.513−2.7932.839−8.374, 2.7880.326 North America vs. Asia0.0050.024−0.043, 0.0520.8511.4282.253−3.001, 5.8560.527Presence of complications of HZ Yes vs. no\-\-\--−4.5091.654−7.761, −1.2570.007*SD* standard deviation, *CI* confidence interval, *VAS* visual analogue scale, *WPQ* Work and Productivity Questionnaire^a^The estimate is the relative effect of the predictor on EQ-5D scores compared to the reference group^b^ Patients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any of the follow-up visits (Visits 2--10) as assessed by the WPQ^c^ Worst pain categories are based on the ZBPI "worst pain in the last 24 h" scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores 4- ≤ 7; severe worst pain = ZBPI score ≥8^d^ Country income classifications are based on the 2016 World Bank economic definitions \[[@CR22]\]. High Income= Canada, South Korea, Taiwan, Argentina; Upper Middle Income= Brazil, Costa Rica, Mexico, Thailand^e^ Asia = Taiwan, Thailand, South Korea; Latin America = Argentina, Brazil, Costa Rica; Mexico; North America = Canada

Discussion {#Sec15}
==========

As reported previously, the results of this analysis demonstrate that shingles has a negative impact on the work and productive life of individuals \[[@CR9]--[@CR11]\]. Individuals experiencing work time loss reported lower health utility scores, at baseline and overall, than their non-work time loss counterparts, with work time loss identified as an independent negative predictor of both the EQ-5D summary scores and the VAS (*p* \< 0.001). Decrease in work effectiveness was also negatively associated with quality of life overall, and in both the WTL and NWTL groups.

Additional predictors of quality of life identified were worst pain score, the presence of HZ complications, and country income (both complications and county income predictors of the EQ-5D VAS only). Although severity of rash was identified as a significant predictor of quality of life, the direction of the prediction is of interest, with more severe rash associated with improved HRQoL. This may be explained by the fact that, due to the inclusion of prevalent cases, there may not be a temporal association between rash assessment and disease onset. Thus, it could be argued that patients with no rash were those for whom rash healing had occurred, and that consequently, these patients experienced an overall longer time elapsed since disease onset. As it has been documented that prolonged pain of HZ has a significant effect on quality of life \[[@CR6], [@CR19]\], the residual post-rash pain experienced by these patients may have resulted in the reporting of lower health utility scores compared to patients assessed earlier in the course of their HZ episode, when rash manifestation was still evident. In our analysis, we have tried to adjust for the effect of time since HZ onset which was not found to have a significant impact on quality of life; however, it is possible that there may be residual confounding.

Overall 57.7% of patients reported missing work for an average (SD) of 9.1 (15.6) days. Days missed is therefore higher than that reported by Drolet et al. (3.4 days) and Singhal et al. (4 days) \[[@CR9], [@CR10]\], however discrepancies in study design may account for these differences: Drolet et al. evaluated HZ patients within 14 days of rash onset, whereas this study's inclusion of prevalent cases may have resulted in patient recall bias leading to an overestimation of HZ-related work time loss. In addition, at baseline, a higher proportion of patients in the WTL group reported a decrease in work effectiveness, indicating that patients who miss work due to their HZ episode are also less productive, and experience increased presenteeism.

Importantly, our findings show that patients reporting work time loss experience lower quality of life as compared to those not reporting work time loss, independently of differences in disease severity and other potential confounders. This suggests that people, at least some, consider work loss in their valuation of health states. Whether the effect of work time loss on quality of life is due to income loss and/or non-monetary factors such as psychological factors, could not be evaluated. In a review paper by Tilling et al., the proportion of patients who considered monetary losses in health state valuations when explicit instruction was not given was found to vary from 6 to 64% across the studies characterized \[[@CR23]\]. In the same paper, significant differences in health care valuations were also observed between groups with and without instruction to consider income. Overall, Tiling et al. concluded that considerable inconsistencies exist between individuals in regards to considering income effects when valuing health states \[[@CR23]\]. Due to differences in respondent characteristics, severity of health states values, measurement technique, and country of conduct, these results, as in the Tilling et al. review, were not consistent across all studies, and two were identified in which a majority of respondents did consider income \[[@CR24], [@CR25]\]. However, the two studies identified report that even with explicit instruction, the effects on income on health care valuations are disputable: Shiroiwa et al. found no significant differences in utility scores between individuals receiving no instruction regarding income, individuals instructed to consider income reduction, and individuals instructed to assume compensation for lost income \[[@CR25]\], and Krol et al. found that explicit instruction on the inclusion of income effects had only some effect on time trade-off (TTO) valuations \[[@CR24]\]. This suggests that the effect of lost income on utility scores is multifaceted, as it may involve social aspects such as human relationships and self-fulfillment, rendering the effects of double counting in calculating cost-effectiveness negligible \[[@CR25]\].

A limitation of the current analysis is that, due to the inclusion of prevalent cases, time since disease onset varied across patients, and may have led to recall bias in the assessment of work time loss since rash onset and the presence of prodromal pain. Furthermore, disease misclassification cannot be ruled out, as laboratory confirmation of VZV was not protocol-mandated. Finally, it is possible that selection bias towards including more severe HZ cases may have been introduced due to the fact that the patient population comprised of patients who sought out medical attention for their HZ episode.

Conclusions {#Sec16}
===========

The results of this study demonstrate that HZ-related reductions in work effectiveness and work time have a negative effect on the quality of life of actively employed individuals, independently of differences in disease severity and other potential confounders. However, it remains to be determined whether patients consider reductions in income when valuating health care states, as the results of studies assessing the unprompted inclusion of the effects of income have reported conflicting results \[[@CR25], [@CR26]\]. In fact, the revised recommendations put forth by the Panel on Cost-Effectiveness in Health and Medicine, in a complete methodological shift, affirm that effects on productivity are unlikely to be captured in the denominator of most preference-based measures, citing inconclusive evidence \[[@CR15]\]. Instead, in reference case analyses conducted under the societal perspective, the Panel advocates for the inclusion of these effects in the numerator of the ICER despite uncertainty with respect to the risk of double counting \[[@CR15]\].
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AIDS

:   Acquired immunodeficiency syndrome

CI

:   Confidence interval

CIS

:   Carcinoma in situ

EQ-5D

:   Euro-QoL 5D questionnaire

GNI

:   Gross national income

HCRU

:   Health care resource utilization

HIV

:   Human immunodeficiency virus

HRQoL

:   Health related quality of life

HZ

:   Herpes Zoster

ICER

:   Incremental cost-effectiveness ratio

IZIQ

:   Initial Zoster Impact Questionnaire

NWTL

:   No work time loss

QoL

:   Quality of life

SD

:   Standard deviation

VAS

:   Visual analogue scale

VZV

:   Varicella zoster virus

WPQ

:   Work and Productivity Questionnaire

WTL

:   Work time loss

ZBPI

:   Zoster Brief Pain Inventory
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